08:26 AM EDT, 06/16/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Monday that its drug Breyanzi achieved "high, lasting response rates" among patients with relapsed or refractory marginal zone lymphoma in a phase 2 study.

The company said 95.5% of 66 evaluable patients showed an overall response, while 62.1% showed a complete response.

At 24 months, 88.6% sustained a response, 85.7% achieved progression-free survival, and 90.4% showed overall survival, the company said.

Median survival for patients with marginal zone lymphoma with multiple relapses is 3 to 5 years, the company said.